Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has met the pre-condition for a potential share alternative offer in its proposed pre-conditional privatization of Henlius by merger. Shareholders have shown indicative interest surpassing the required 2% threshold, yet the final decision to make the offer remains at the discretion of the offeror. Investors are cautioned as the merger’s completion is conditional and not guaranteed.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
